StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
103
This year
3
Publishing Date
2023 - 06 - 28
2
2023 - 05 - 31
3
2023 - 05 - 30
2
2023 - 05 - 29
4
2023 - 05 - 26
3
2022 - 11 - 08
2
2022 - 11 - 02
1
2022 - 10 - 31
1
2022 - 09 - 28
1
2022 - 09 - 06
1
2022 - 08 - 22
1
2022 - 08 - 09
1
2022 - 08 - 08
1
2022 - 08 - 01
1
2022 - 07 - 11
1
2022 - 06 - 23
1
2022 - 06 - 08
1
2022 - 05 - 26
1
2022 - 05 - 18
1
2022 - 05 - 10
1
2022 - 04 - 28
1
2022 - 04 - 06
1
2022 - 04 - 05
1
2022 - 03 - 31
1
2022 - 02 - 28
1
2022 - 02 - 18
2
2022 - 02 - 16
1
2022 - 02 - 04
1
2022 - 01 - 31
1
2022 - 01 - 30
2
2022 - 01 - 21
1
2022 - 01 - 14
1
2021 - 12 - 31
1
2021 - 12 - 08
1
2021 - 12 - 02
2
2021 - 11 - 08
1
2021 - 11 - 01
1
2021 - 10 - 28
1
2021 - 10 - 06
1
2021 - 09 - 30
2
2021 - 08 - 09
1
2021 - 08 - 02
1
2021 - 07 - 12
1
2021 - 06 - 29
1
2021 - 06 - 07
1
2021 - 05 - 19
2
2021 - 05 - 14
1
2021 - 05 - 11
1
2021 - 05 - 06
1
2021 - 05 - 03
2
2021 - 04 - 28
1
2021 - 04 - 27
1
2021 - 04 - 26
1
2021 - 04 - 15
1
2021 - 03 - 15
1
2021 - 03 - 01
2
2021 - 02 - 22
1
2020 - 12 - 04
2
2020 - 12 - 02
1
2020 - 12 - 01
1
Sector
Commercial services
1
Finance
6
Health technology
103
Industrial services
1
Producer manufacturing
1
Technology services
1
Tags
100
3
Acquire
1
Acquisition
2
Acquisition corp
1
Als
9
Application
4
Approval
9
Berubicin
24
Biopharma
1
Biotech-bay
1
Ces
5
Change
1
Commercial
1
Companies
2
Company announcement
3
Conference
7
Covid-19
1
Deadline
7
Designation
5
Disease
4
Drug
5
Earnings
6
Europe
2
Events
3
Fast track
3
Fast track designation
2
Fda
12
Fda-approvals
2
Financial
4
Financial results
9
Friedreich's ataxia
2
Friedreich’s ataxia
6
Glioblastoma
13
Global
6
Growth
2
Kidney
4
Lone-star-bio
26
Market
2
N/a
48
Offering
4
Ongoing
10
People
3
Pharmaceuticals
21
Potential
14
Presentation
5
Program
3
Regulatory
3
Report
3
Research
5
Results
17
Review
2
Skyclarys
2
Study
7
Submission
3
Switzerland
3
Syndros
4
Therapeutics
2
Treatment
28
Trial
11
Update
6
Entities
Abbott laboratories
2
Abbvie inc.
1
Aldeyra therapeutics, inc.
1
Alnylam pharmaceuticals, inc.
1
Amgen inc.
1
Apollo endosurgery, inc.
1
Astrazeneca plc
1
Biogen inc.
3
Catalent, inc.
1
Chinook therapeutics, inc.
1
Cns pharmaceuticals, inc.
29
Docusign, inc.
1
Eli lilly and company
2
Franchise group, inc.
1
Ies holdings, inc.
1
Karyopharm therapeutics inc.
2
Kiniksa pharmaceuticals, ltd.
1
Kornit digital ltd.
1
Moleculin biotech, inc.
2
Novartis ag
1
Novo nordisk a/s
2
Pfizer, inc.
1
Phathom pharmaceuticals, inc.
7
Pulse biosciences, inc
1
Rallybio corp
1
Reata pharmaceuticals, inc.
103
Replimune group, inc.
1
Sanofi
4
Sarepta therapeutics, inc.
1
Sierra oncology, inc.
1
Stoke therapeutics, inc.
1
Summit therapeutics inc.
1
Texas capital bancshares, inc.
6
Verona pharma plc
1
Xencor, inc.
1
Symbols
ABBV
1
ABT
2
ALDX
1
ALNY
1
AMGN
1
APEN
1
AZN
1
BIIB
3
CNSP
29
CTLT
1
DOCU
1
FRG
1
IESC
1
KDNY
1
KNSA
1
KPTI
2
KRNT
1
LLY
2
MBRX
2
NVO
2
NVS
1
NVSEF
1
PFE
1
PHAT
7
PLSE
1
REPL
1
RETA
103
RLYB
1
SMMT
1
SNY
4
SNYNF
3
SRPT
1
SRRA
1
STOK
1
TCBI
6
VRNA
1
XNCR
1
Exchanges
Nasdaq
103
Nyse
6
Crawled Date
2023 - 06 - 28
2
2023 - 05 - 31
3
2023 - 05 - 30
2
2023 - 05 - 29
4
2023 - 05 - 26
3
2022 - 11 - 08
2
2022 - 11 - 02
1
2022 - 11 - 01
1
2022 - 09 - 28
1
2022 - 09 - 06
1
2022 - 08 - 22
1
2022 - 08 - 09
1
2022 - 08 - 08
1
2022 - 08 - 01
1
2022 - 07 - 11
1
2022 - 06 - 23
1
2022 - 06 - 08
1
2022 - 05 - 26
1
2022 - 05 - 18
1
2022 - 05 - 10
1
2022 - 04 - 28
1
2022 - 04 - 06
1
2022 - 04 - 05
1
2022 - 03 - 31
1
2022 - 02 - 28
1
2022 - 02 - 18
2
2022 - 02 - 16
1
2022 - 02 - 04
1
2022 - 01 - 31
1
2022 - 01 - 30
2
2022 - 01 - 21
1
2022 - 01 - 14
1
2021 - 12 - 31
1
2021 - 12 - 08
1
2021 - 12 - 02
2
2021 - 11 - 08
1
2021 - 11 - 01
1
2021 - 10 - 28
1
2021 - 10 - 06
1
2021 - 09 - 30
2
2021 - 08 - 09
1
2021 - 08 - 02
1
2021 - 07 - 12
1
2021 - 06 - 29
1
2021 - 06 - 07
1
2021 - 05 - 19
2
2021 - 05 - 14
1
2021 - 05 - 11
1
2021 - 05 - 06
1
2021 - 05 - 03
2
2021 - 04 - 28
1
2021 - 04 - 27
1
2021 - 04 - 26
1
2021 - 04 - 15
1
2021 - 03 - 15
1
2021 - 03 - 01
2
2021 - 02 - 22
1
2020 - 12 - 04
2
2020 - 12 - 02
1
2020 - 12 - 01
1
Crawled Time
00:00
3
02:00
4
03:00
2
04:00
1
05:00
2
08:00
1
08:20
1
09:00
9
10:00
2
11:00
8
12:00
13
12:15
2
12:20
2
12:30
2
13:00
10
13:15
1
13:20
2
13:30
1
14:00
6
14:20
2
14:30
1
15:00
5
15:30
1
16:00
3
17:00
2
18:00
3
19:00
2
20:00
2
20:20
2
21:00
3
21:05
1
22:00
3
23:00
1
Source
apolloendo.com
1
www.biospace.com
52
www.globenewswire.com
17
www.prnewswire.com
33
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
entities :
Reata pharmaceuticals, inc.
symbols :
RETA
save search
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published:
2024-01-17
(Crawled : 14:30)
- biospace.com/
CNSP
|
$0.204
26K
|
Health Technology
|
-72.24%
|
O:
5.82%
H:
7.57%
C:
-7.32%
berubicin
treatment
pharmaceuticals
glioblastoma
study
Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth by 2032, Predicts DelveInsight | Leading Companies - ACELYRIN, Genentech, ChemoCentryx, Travere Therapeutics, Boehringer Ingelheim, Chinook Therapeutics
Published:
2024-01-10
(Crawled : 22:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
600K
|
Health Technology
|
-10.95%
|
O:
1.1%
H:
0.0%
C:
0.0%
NVO
|
$123.01
0.21%
2.6M
|
Health Technology
|
14.59%
|
O:
-0.33%
H:
0.35%
C:
-1.5%
LLY
|
$728.765
-2.3%
1.5M
|
Health Technology
|
19.13%
|
O:
0.67%
H:
0.85%
C:
0.21%
SNY
|
News
|
$46.34
2.09%
620K
|
Health Technology
|
-12.45%
|
O:
0.69%
H:
0.0%
C:
0.0%
ALDX
|
News
|
$3.85
-3.27%
130K
|
Health Technology
|
19.16%
|
O:
-1.8%
H:
0.46%
C:
-2.44%
companies
therapeutics
growth
market
Kirby McInerney LLP Announces Pendency of Class Action and Proposed Settlement Involving Purchasers of Reata Pharmaceuticals, Inc. Common Stock
Published:
2024-01-08
(Crawled : 13:00)
- prnewswire.com
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
Email alert
Add to watchlist
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
Published:
2023-11-22
(Crawled : 15:00)
- biospace.com/
CNSP
|
$0.204
26K
|
Health Technology
|
-90.43%
|
O:
3.35%
H:
25.0%
C:
4.17%
berubicin
ongoing
pharmaceuticals
study
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
Published:
2023-11-07
(Crawled : 15:00)
- biospace.com/
ABBV
|
News
|
$166.43
1.08%
2M
|
Health Technology
|
16.48%
|
O:
-0.28%
H:
0.0%
C:
0.0%
SMMT
A
|
$3.445
-1.85%
450K
|
Health Technology
|
63.76%
|
O:
-0.46%
H:
6.68%
C:
-11.75%
PLSE
|
$7.2
-2.17%
30K
|
Health Technology
|
43.93%
|
O:
0.39%
H:
6.43%
C:
1.92%
BIIB
|
$191.45
0.49%
310K
|
Health Technology
|
-21.51%
|
O:
-0.82%
H:
0.73%
C:
-0.4%
ALNY
|
News
|
$146.34
0.81%
64K
|
Health Technology
|
-13.16%
|
O:
1.06%
H:
2.42%
C:
0.76%
therapeutics
financial
results
CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date
Published:
2023-10-11
(Crawled : 13:00)
- biospace.com/
CNSP
|
$0.204
26K
|
Health Technology
|
-81.31%
|
O:
-2.8%
H:
18.26%
C:
13.46%
rapid
berubicin
treatment
ongoing
glioblastoma
study
Biogen Completes Acquisition of Reata Pharmaceuticals
Published:
2023-09-26
(Crawled : 13:00)
- globenewswire.com
BIIB
|
$191.45
0.49%
310K
|
Health Technology
|
-23.48%
|
O:
-0.02%
H:
1.37%
C:
1.21%
acquisition
pharmaceuticals
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
Published:
2023-08-14
(Crawled : 13:00)
- biospace.com/
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
2.91%
|
O:
0.31%
H:
1.04%
C:
0.76%
CNSP
|
$0.204
26K
|
Health Technology
|
-90.15%
|
O:
-2.46%
H:
2.53%
C:
-10.61%
berubicin
pharmaceuticals
therapy
results
study
CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published:
2023-08-03
(Crawled : 12:20)
- biospace.com/
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
3.77%
|
O:
0.07%
H:
0.83%
C:
0.57%
CNSP
|
$0.204
26K
|
Health Technology
|
-90.65%
|
O:
0.93%
H:
3.24%
C:
1.39%
berubicin
update
treatment
ongoing
pharmaceuticals
trial
glioblastoma
study
Biogen to Acquire Reata Pharmaceuticals
Published:
2023-07-28
(Crawled : 11:00)
- globenewswire.com
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
58.78%
|
O:
51.72%
H:
1.55%
C:
1.52%
BIIB
|
$191.45
0.49%
310K
|
Health Technology
|
-25.74%
|
O:
0.19%
H:
1.88%
C:
0.73%
pharmaceuticals
acquire
Reata Pharmaceuticals Announces Approval of Prior Approval Supplement for SKYCLARYS® (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich’s Ataxia
Published:
2023-06-28
(Crawled : 08:00)
- biospace.com/
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
86.56%
|
O:
6.1%
H:
5.34%
C:
0.82%
skyclarys
approval
pharmaceuticals
commercial
Chronic Kidney Disease - Market Insight, Epidemiology and Market Forecast 2023-2032: With Focus on United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan
Published:
2023-06-28
(Crawled : 02:00)
- prnewswire.com
NVO
|
$123.01
0.21%
2.6M
|
Health Technology
|
-20.16%
|
O:
1.47%
H:
0.0%
C:
-0.94%
LLY
|
$728.765
-2.3%
1.5M
|
Health Technology
|
61.63%
|
O:
0.86%
H:
0.0%
C:
-2.09%
SNY
|
News
|
$46.34
2.09%
620K
|
Health Technology
|
-15.05%
|
O:
0.75%
H:
0.0%
C:
0.0%
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
86.56%
|
O:
6.1%
H:
5.34%
C:
0.82%
disease
japan
kidney
market
Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS® (Omaveloxlone) NDA Prior Approval Supplement
Published:
2023-06-16
(Crawled : 10:00)
- biospace.com/
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
84.13%
|
O:
3.5%
H:
0.81%
C:
-3.62%
skyclarys
fda
approval
pharmaceuticals
Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer
Published:
2023-06-13
(Crawled : 12:00)
- biospace.com/
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
73.89%
|
O:
-0.83%
H:
7.38%
C:
6.11%
pharmaceuticals
research
RETA FRAUD ALERT: Jakubowitz Law is Investigating Reata Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws
Published:
2023-06-09
(Crawled : 10:00)
- prnewswire.com
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
83.17%
|
O:
-0.15%
H:
0.96%
C:
-0.17%
potential
RETA ALERT: The Law Offices of Vincent Wong Investigate Reata Pharmaceuticals, Inc. for Potential Violations of Securities Laws
Published:
2023-05-31
(Crawled : 09:00)
- prnewswire.com
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
92.15%
|
O:
0.02%
H:
1.4%
C:
0.37%
PHAT
|
$9.175
-3.22%
220K
|
Health Technology
|
-14.04%
|
O:
0.88%
H:
4.78%
C:
2.26%
potential
TCBI ALERT: The Law Offices of Vincent Wong Investigate Texas Capital Bancshares, Inc. for Potential Violations of Securities Laws
Published:
2023-05-31
(Crawled : 09:00)
- prnewswire.com
TCBI
|
News
|
$57.45
2.63%
130K
|
Finance
|
11.86%
|
O:
-0.31%
H:
0.33%
C:
-3.51%
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
92.15%
|
O:
0.02%
H:
1.4%
C:
0.37%
PHAT
|
$9.175
-3.22%
220K
|
Health Technology
|
-14.04%
|
O:
0.88%
H:
4.78%
C:
2.26%
potential
PHAT ALERT: The Law Offices of Vincent Wong Investigate Phathom Pharmaceuticals, Inc. for Potential Violations of Securities Laws
Published:
2023-05-31
(Crawled : 09:00)
- prnewswire.com
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
92.15%
|
O:
0.02%
H:
1.4%
C:
0.37%
PHAT
|
$9.175
-3.22%
220K
|
Health Technology
|
-14.04%
|
O:
0.88%
H:
4.78%
C:
2.26%
potential
RETA FRAUD ALERT: Jakubowitz Law is Investigating Reata Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws
Published:
2023-05-30
(Crawled : 09:00)
- prnewswire.com
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
86.72%
|
O:
-0.34%
H:
0.55%
C:
-2.5%
PHAT
|
$9.175
-3.22%
220K
|
Health Technology
|
-16.67%
|
O:
0.26%
H:
2.71%
C:
-3.31%
potential
PHAT FRAUD ALERT: Jakubowitz Law is Investigating Phathom Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws
Published:
2023-05-30
(Crawled : 09:00)
- prnewswire.com
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
86.72%
|
O:
-0.34%
H:
0.55%
C:
-2.5%
PHAT
|
$9.175
-3.22%
220K
|
Health Technology
|
-16.67%
|
O:
0.26%
H:
2.71%
C:
-3.31%
potential
← Previous
1
2
3
4
5
6
Next →
Gainers vs Losers
77%
23%
Top 10 Gainers
AGBA
|
News
|
$1.22
205.0%
86M
|
Finance
EGOX
|
$0.054
50.0%
290M
|
CHRO
|
$1.66
35.51%
70K
|
n/a
INDO
|
$5.43
33.09%
10M
|
Energy Minerals
NVFY
|
$2.71
28.44%
31M
|
Consumer Durables
ZCMD
|
$1.86
28.28%
29M
|
Commercial Services
RWOD
|
$10.08
26.05%
5.6M
|
n/a
HUSA
4
|
$2.07
23.95%
2.1M
|
Energy Minerals
TPET
|
$0.4001
22.02%
35M
|
n/a
SRFM
4
|
$0.6
21.29%
850K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.